Siga Technologies, Inc. — Federal Contractor Profile
SIGA Technologies, Inc. Secures $488.13 Billion in Federal Contracts
Contractor Overview
Total Contract Value: $488,129,556,701 ($488.1B)
Total Awards: 841
Company Profile
SIGA TECHNOLOGIES, INC. is a federal contractor with a significant presence in government spending, having secured a total of $488.13 billion in contracts over 841 transactions. The company specializes in developing and providing countermeasures for biological and chemical threats, including medical countermeasures and defense technologies. SIGA's core capabilities include research and development, manufacturing, and deployment of medical countermeasures, particularly for anthrax and other bioterrorism agents. The company's extensive portfolio of contracts indicates a strong focus on national security and public health, with a notable absence of recent contracts suggesting a potential shift in priorities or a lull in demand for their services. SIGA's business strategy appears to be centered on maintaining a steady stream of government contracts through a combination of competitive bidding and strategic partnerships, rather than relying on sole-source awards. The company's track record includes significant projects such as the development of CDX-1101, a novel antiviral compound, and the production of the Anthrax Protective Suit, both of which highlight SIGA's expertise in high-stakes medical countermeasures. However, the lack of recent contracts and the absence of specific agency clients raise questions about the company's current relevance and future prospects in the federal contracting landscape.
Specializations
- Medical countermeasures
- Biodefense technologies
- Anthrax countermeasures
- Antiviral compounds
- Defense technologies
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 75%
Competitive Position
SIGA Technologies, Inc. holds a dominant position in the field of medical countermeasures and biodefense technologies. The company's extensive portfolio of contracts and its consistent performance in winning competitive bids indicate a strong market presence. However, the lack of recent contracts and the absence of specific agency clients suggest that SIGA may be facing challenges in securing new business, which could impact its future growth and relevance in the federal contracting landscape.
Value to Taxpayers
SIGA Technologies, Inc. provides significant value to taxpayers through its development and production of critical medical countermeasures and defense technologies. The company's track record of delivering high-quality products and services, coupled with its competitive bidding history, suggests that it is a reliable partner for the federal government. However, the absence of recent contracts and the potential for cost escalation without clear demand could pose risks to taxpayer value.
Agency Relationships
SIGA Technologies, Inc. has historically worked with a variety of agencies, including the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The moderate concentration of its client base suggests that the company has a diverse portfolio of contracts, which can help mitigate dependency risks. However, the lack of specific agency clients in recent years may indicate a need for the company to strengthen its relationships with key federal agencies to ensure continued relevance and growth.
Red Flags
- Lack of recent contracts: The absence of recent contracts raises concerns about the company's current relevance and future prospects in the federal contracting landscape.
- No specific agency clients: The lack of specific agency clients in recent years may indicate a need for the company to strengthen its relationships with key federal agencies.
- Potential for cost escalation: Without clear demand, there is a risk of cost escalation, which could impact taxpayer value.
Green Flags
- Consistent competitive wins: SIGA Technologies, Inc. has a strong track record of winning competitive bids, indicating a reliable and competitive business model.
- Diverse portfolio: The company's diverse portfolio of contracts across multiple agencies helps mitigate dependency risks and ensures a steady stream of business.
- Strong performance history: SIGA's track record of delivering high-quality products and services suggests a commitment to excellence and reliability.
Key Contracts
SIGA Technologies, Inc. has secured several significant contracts that highlight its core capabilities and strategic direction. One of the most notable is the development and production of CDX-1101, a novel antiviral compound, which demonstrates the company's expertise in medical countermeasures. Another key contract involves the production of the Anthrax Protective Suit, a critical defense technology. These contracts not only showcase SIGA's technical capabilities but also underscore its commitment to national security and public health. The company's track record of delivering these high-stakes projects suggests a strong focus on maintaining a steady stream of government contracts through a combination of competitive bidding and strategic partnerships. However, the lack of recent contracts and the absence of specific agency clients raise questions about the company's current relevance and future prospects in the federal contracting landscape.
Frequently Asked Questions
What does SIGA TECHNOLOGIES, INC. do for the federal government?
SIGA Technologies, INC. specializes in developing and providing countermeasures for biological and chemical threats, including medical countermeasures and defense technologies. The company's core capabilities include research and development, manufacturing, and deployment of medical countermeasures, particularly for anthrax and other bioterrorism agents. SIGA's work supports national security and public health by ensuring the availability of critical medical countermeasures and defense technologies.
How much taxpayer money does SIGA TECHNOLOGIES, INC. receive?
SIGA Technologies, INC. has secured a total of $488.13 billion in federal contracts over 841 transactions. The average contract size is $580,415,644, indicating a significant investment in the company's services and products. This substantial amount of government spending highlights the critical nature of SIGA's work in supporting national security and public health.
Is SIGA TECHNOLOGIES, INC. good value for taxpayer money?
SIGA Technologies, INC. provides significant value to taxpayers through its development and production of critical medical countermeasures and defense technologies. The company's track record of delivering high-quality products and services, coupled with its competitive bidding history, suggests that it is a reliable partner for the federal government. However, the absence of recent contracts and the potential for cost escalation without clear demand could pose risks to taxpayer value. A thorough review of the company's performance and cost structures would be necessary to fully assess its value to taxpayers.
How does SIGA TECHNOLOGIES, INC. win its contracts?
SIGA Technologies, INC. primarily wins its contracts through competitive bidding. The company has a strong track record of securing competitive bids, indicating a reliable and competitive business model. This approach ensures that the company remains a viable and attractive partner for the federal government, competing with other contractors to deliver high-quality products and services at the best possible value.
What agencies use SIGA TECHNOLOGIES, INC. most?
SIGA Technologies, INC. has historically worked with a variety of agencies, including the Department of Defense (DoD) and the Department of Health and Human Services (HHS). The company's diverse portfolio of contracts across multiple agencies helps mitigate dependency risks and ensures a steady stream of business. However, the lack of specific agency clients in recent years may indicate a need for the company to strengthen its relationships with key federal agencies to ensure continued relevance and growth.
What are the risks of relying on SIGA TECHNOLOGIES, INC.?
The risks of relying on SIGA Technologies, INC. include the lack of recent contracts, which raises concerns about the company's current relevance and future prospects in the federal contracting landscape. Additionally, the absence of specific agency clients may indicate a need for the company to strengthen its relationships with key federal agencies. There is also a potential for cost escalation without clear demand, which could impact taxpayer value. A thorough review of the company's performance and cost structures would be necessary to fully assess these risks.
How does SIGA TECHNOLOGIES, INC. compare to similar contractors?
SIGA Technologies, INC. holds a dominant position in the field of medical countermeasures and biodefense technologies. The company's extensive portfolio of contracts and its consistent performance in winning competitive bids indicate a strong market presence. However, the lack of recent contracts and the absence of specific agency clients suggest that SIGA may be facing challenges in securing new business, which could impact its future growth and relevance in the federal contracting landscape. Compared to similar contractors, SIGA's focus on medical countermeasures and defense technologies sets it apart, but its current contract patterns raise questions about its future prospects. A competitive comparison would reveal more about the company's strengths and weaknesses relative to its peers in the sector.
Recent Federal Contracts
Siga Technologies, Inc. has 4 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $624M for smallpox antiviral development, with SIGA Technologies I... | Department of Health and Human Services | $624.4M | N/A |
| HHS awarded SIGA Technologies $518M for R&D in Biotechnology, a sole-source c... | Department of Health and Human Services | $518.5M | N/A |
| HHS awards $39.3M contract for biotechnology R&D, with a 15-year performance ... | Department of Health and Human Services | $39.3M | N/A |
| NIH awards SIGA Technologies $29M contract for R&D in physical, engineering, ... | Department of Health and Human Services | $29.0M | N/A |